| Acquired Immunodeficiency Syndrome |
YF-HIV, NCT03132311: Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals |
|
|
| Recruiting | 4 | 400 | RoW | Yellow Fever vaccination (17 DD Biomanguinhos) | Oswaldo Cruz Foundation | HIV Infections | 12/18 | 12/28 | | |
STAR, NCT03037372: Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial |
|
|
| Not yet recruiting | 3 | 320 | NA | ART, Atorvastatin, Atovastatin adjunct therapy, ART, Rosuvastatin, Rosuvastatin adjunct therapy, ART, No statin, No statin adjunct therapy, Healthy-HIV-negative, HIV-negative controls | Makerere University, University of Oxford, Case Western Reserve University | HIV Infection | 06/22 | 12/22 | | |
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
|
|
| Active, not recruiting | 2 | 60 | US | VRX496-Modified Autologous T cells | VIRxSYS Corporation | HIV Infection | 11/08 | 06/23 | | |
| Active, not recruiting | 2 | 40 | US | VRX496-transduced autologous CD4 T cells | VIRxSYS Corporation | HIV Infections | 01/09 | 06/23 | | |
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program |
|
|
| No Longer Available | N/A | | US | Atazanavir (BMS-232632) | Bristol-Myers Squibb | HIV Infections | | 07/03 | | |
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
|
|
| No Longer Available | N/A | | US | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada |
|
|
| No Longer Available | N/A | | Canada | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00801515: A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 |
|
|
| No Longer Available | N/A | | Canada | Maraviroc, Celsentri | ViiV Healthcare, Pfizer | HIV | 07/11 | 07/11 | | |
NCT02028819: Compassionate Use of Ibalizumab for the Treatment of HIV Infection |
|
|
| No Longer Available | N/A | | US | Dolutegravir Sodium Monohydrate, TIVICAY, Ibalizumab, TMB-355 | University of Colorado, Denver | Human Immunodeficiency Virus (HIV) | 02/14 | 02/14 | | |
NCT02069652: Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention, |
|
|
| No Longer Available | N/A | | RoW | Lifestyle Counseling | Kaohsiung Medical University Chung-Ho Memorial Hospital | HIV | 12/14 | | | |
NCT00975546: HIV-discordant Couple Intrauterine Insemination |
|
|
| No Longer Available | N/A | | US | Sperm washing and testing for HIV contamination, Intrauterine Insemination | University of Missouri-Columbia | Infertility, HIV Infections | | | | |
NCT02712671: Testing for Tuberculosis in the United Kingdom HIV Infected Population |
|
|
| Active, not recruiting | N/A | 300 | Europe | Chest radiograph, Chest X ray, Blood interferon gamma release assay, Blood IGRA, TSpot.TB, Tuberculin skin testing (TST), TST, Mantoux test, Sputum induction for mycobacterial microscopy and culture, Mycobacterium tuberculosis polymerase chain reaction testing, TB PCR, GeneXpert MTB/RIF, Spirometry, Lung function | University College, London | HIV, Latent Tuberculosis | 02/16 | 09/24 | | |
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc |
|
|
| No Longer Available | N/A | | Europe, RoW | Continued Access Arm | ViiV Healthcare, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | | | | |
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study |
|
|
| No Longer Available | N/A | | US | PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5 | CytoDyn, Inc., Amarex Clinical Research | HIV | | | | |
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
|
|
| No Longer Available | N/A | | NA | Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus (HIV) | | | | |
NCT03010332: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease |
|
|
| No Longer Available | N/A | | NA | Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs), ATA230 | Atara Biotherapeutics | CMV Viremia, CMV Disease | | | | |
NCT03149354: Prevalence of Thyroid Function Abnormalities in HIV-infected Patients |
|
|
| Recruiting | N/A | 104 | Europe | Assay of TSH, FT3 and FT4 by immuno-radiometric method | Centre Hospitalier Universitaire, Amiens | Thyroid, HIV Infections | 12/22 | 12/22 | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study |
|
|
| Recruiting | N/A | 2017 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 01/25 | 01/25 | | |
| Recruiting | N/A | 1000 | RoW | | Infectious Diseases Institute | HIV/AIDS | 01/25 | 01/25 | | |
NCT02149004: German Centre for Infection Research HIV Translational Platform |
|
|
| Recruiting | N/A | 10000 | Europe | | University Hospital of Cologne, German Center for Infection Research, German Federal Ministry of Education and Research | HIV | 01/35 | 01/35 | | |